Právní předpis byl sestaven k datu 12.01.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx generální xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx rok 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu.
S xxxxx zněním Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx České xxxxxxxxx x xxxxxxxxx republiky xxxxxxxx listinu x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx xxxxxxxxx vstoupilo x xxxxxxxx dne 18. xxxxxx 2024 x xxxxxxxxx Přílohu X xxx xxx 2023, platnou xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx pro Českou xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X pro xxx 2024 x její xxxxxxx do českého xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;
Xxxxxxx:
x z. XXXx. Xxxxxx, Ph.D., XX.X., x. r.
vrchní xxxxxxx xxxxx právní a xxxxxxxxxx
&xxxx;
Xxxxxxx č. 1
Překlad xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx
Xxxx
Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx xx xxxxxxx Xxxxxxxxxxx standard v xxxxx Xxxxxxxxx antidopingového xxxxxxxx.
Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Seznam je xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x metod xxxx xxxxxxxxx XXXX a xxxx xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx v xxxxxxxxxx.
Xxxx jsou uvedeny xxxxxxx xxxxx xxxxxxxxx x tomto Seznamu xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx xxxxxxx
Xxxxx XXXX pro xxxx xxxxx neschválila xxxx xxxxxx, xx období Xxx xxxxxxx x xxxxxx obdobím začínajícím xxxxx před xxxxxxx (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Sportovec xxxxxxxxx, xx do konce Xxxxxxx a procesu xxxxxx Vzorku.
Zakázané stále
To xxxxxxx, xx xxxx xxxxx xxxx metoda xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, jak je xxxxxxxxxx v Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „xxx účely xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Specifickými látkami, x výjimkou xxxx xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Žádná Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Seznamu xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx xxxxxx.“ Podle xxxxxxxxx x xxxxxx „Xxxxxxxxxx látky x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx považovány xx xxxx xxxxxxxx xxxx xxxx nebezpečné xxx xxxx xxxxxxxxx xxxxx xxxx metody. Xxx spíše o xxxxx x metody, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx účelu xxx xx zlepšení xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Návykové látky xxxxxxxxxx xxxx látky, xxxxx xxxx jako xxxxxx xxxxxxxx x xxxxxx xxxxxx častého xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxx xxxxx: kokain, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 NESCHVÁLENÉ XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX I MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.
Jakákoliv xxxxxxxxxxxxxx látka, xx xxxxxx se xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Xxxxxxx a xxxxx není x xxxxxxxx době xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx u xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx zakázána stále.
Tato xxxxx zahrnuje xxxxx xxxxxxx látek, mimo xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) a aktivátory xxxxxxxxx (xxxx. Xxxxxxxxxxx x Tirasemtiv).
S1 XXXXXXXXXX XXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Nespecifické xxxxx.
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
X1.1. XXXXXXXXXX ANDROGENNÍ STEROIDY (XXX)
Xxx xxxxxxxxx podání, xxxx jiné xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol) |
• |
formebolon |
|
|
• |
1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (androst-4-en-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion) |
• |
metandriol |
|
|
• |
7ɑ-hydroxy-DHEA |
• |
metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
|
|
• |
7-xxxx-XXXX |
&xxxx;• |
xxxxxxxxxxxxxx |
|
|
• |
11ß-xxxxx-19-xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-diol) |
• |
metyltestosteron |
|
|
• |
19-norandrostenedion (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on) |
|
|
• |
Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxx (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (androsta-1,4-dien-3,17-dion) |
• |
oxandrolon |
|
|
• |
calusteron |
• |
oxymesteron |
|
|
• |
klostebol |
• |
oxymetolon |
|
|
• |
danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on) |
• |
prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on) |
• |
testosteron |
|
|
• |
epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT) |
a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX XXXXXXXXXX LÁTKY
Mimo xxxx xxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, enobosarm (xxxxxxx), XXX-4033 (ligandrol), XXX140, X-23 a XX-11], zeranol a xxxxxxxxxx.
X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX A XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě jsou Xxxxxxxxxxxx látky.
Následující látky x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky jsou xxxxxxxx.
X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptorů, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx EPO, [xxxx. EPO-Fc, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx a xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.
X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; molidustat (BAY 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (XXX-6548); xenon.
S2.1.3 Xxxxxxxxxx GATA, xxxx. X-11706.
X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX HORMONY A XXXXXX XXXXXXXXXX FAKTORY
S2.2.1 Xxxxxxx stimulující testosteron x xxxx, xxxx xxxx včetně:
• xxxxxxxx xxxxxxxxxxxx (XX),
• luteinizační xxxxxx (XX),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),
&xxxx;• xxxxxxxxxx x jeho agonistické xxxxxxx.
X2.2.2 Kortikotropiny a xxxxxx uvolňující xxxxxxx, xxxx. kortikorelin x xxxxxxxxxxxxx.
X2.2.3 Růstový xxxxxx (XX), jeho xxxxxxx x xxxxxxxxx, mimo xxxx xxxxxx:
• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, somapacitan a xxxxxxxxxx,
• xxxxxxxxx růstového xxxxxxx, xxxx. XXX-9604 x xXX 176–191.
X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:
• xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x jeho analogy, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x tesamorelin,
• xxxxxxxxxxx růstového xxxxxxx (XXX) x xxxxxx xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx XX (XXXX) [např. alexamorelin, xxxxxxxxxx (hexarelin), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 x XXXX-6].
X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX
Xxxx jiné xxxxxx:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxxxxxxx růstový xxxxxx (XXX)
• růstový xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x jeho analogy
• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)
• thymosin-β4 x jeho xxxxxxxx, xxxx. XX-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)
x xxxxx xxxxxxx faktory xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx vazech, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx látky v xxxx xxxxx xxxx Xxxxxxxxxx látky.
Všichni selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx jakékoliv dávce;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx za 24 xxxxx;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 mikrogramů xx 24 hodin.
POZNÁMKA
Přítomnost xxxxxxxxxxx x moči x xxxxxxxx xxxxxx xxx 1000 xx/xx nebo xxxxxxxxxxx x množství xxxxxx xxx 40 xx/xx neodpovídá terapeutickému xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), pokud Sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl důsledkem xxxxxxxxxxxx xxxxx (inhalační) xx xx xxxx xxxxxxx xxxxxxxxx dávky.
S4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxxx xxxxx ve xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.
Xxxxx xxxxxxxx xx xxxx X4.3 a X4.4 xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory jsou xxxxxxxx.
X4.1. INHIBITORY XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol) |
• |
androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx xxxx včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. LÁTKY ZABRAŇUJÍCÍ XXXXXXXX RECEPTORU AKTIVINU XXX
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx aktivin X |
• |
xxxxxxxxxx xxxxxxxxxx, např.: |
|
|
• |
konkurenty receptoru xxxxxxxx IIB, např.: |
- xxxxx snižující xxxx xxxxxx expresi xxxxxxxxxx |
||
|
- xxxxxxx receptory xxxxxxxx (xxxx. ACE-031) |
- xxxxxxxx xxxxxx myostatin (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx xxxxxxxxx aktivinu XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx neutralizující xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. METABOLICKÉ XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (XX1516, XX501516) x agonisté Xxx-xxxɑ , xxxx. XX9009, XX9011
X4.4.2 insuliny a xxxxxxxx xxxxxxxx
X4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX A XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI I XXXX SOUTĚŽ)
Všechny zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx diuretika x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, jsou xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Xxxxxxxxx, xxxx xxxx.:
xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; kanrenon; chlortalidon; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxx; metolazon; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Xxxxxxx, xxxx. xxxxxxxxxx, mozavaptan, xxxxxxxxx;
• Plazmatické xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx.
XXXXXXX
• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamid, xxxxxxxxxxx);
• xxxxxxx podání xxxxxxxxxxx x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx xxxx lokálního xxxxxx felypresinu x xxxxxxxx xxxxxxxxx), bude xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na tuto xxxxx navíc x xx, která xxx xxxx udělena xx xxxxxxxxxx nebo jinou xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx metody x xxxx xxxxx jsou Xxxxxxxxxxxx s xxxxxxxx xxxxx v X2.2, xxx jsou Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx následující:
M1.1. Xxxxxx xxxx opětovné xxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, allogenní (xxxxxxxxx) xxxx heterologní xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx xx oběhového xxxxxxx x xxxxxxxx xxxxxxxx plazmy nebo xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.
X1.2. Xxxxx zvyšování xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx produkty, např. xxxxxx náhražky xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.
M1.3. Jakákoliv xxxxx intravaskulární xxxxxxxxxx x xxxx nebo x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ A XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X2.1. Xxxxxxxxx nebo Xxxxx x podvod xx účelem porušit xxxxxxxxx x xxxxxxxx Xxxxxx odebraných xxx Xxxxxxxxx kontrole.
Mimo jiné xxxxxx:
Xxxxxx x/xxxx úprava Xxxxxx, např. xxxxxxxx xxxxxxx xx Xxxxxx.
X2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx než xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X3. GENOVÝ X XXXXXXX XXXXXX
X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
X3.1. Použití xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx, xxxxx xxxxx změnit sekvence xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx mechanismem. Xx mimo xxxx xxxxxxxx xxxxxxxxxxx úprav xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ PŘI XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Specifické xxxxx x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx jsou Nespecifické xxxxx.
Xxxxxxxx látky x xxxx xxxxx: kokain x metylendioxymetamfetamin (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, xxxxxx všech xxxxxxxxx izomerů, xxxx. x- x x-, xxxx zakázána.
Stimulancia zahrnují:
S6.A: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, který xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.
X6.X: SPECIFICKÁ XXXXXXXXXXX
Xxxx jiné xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-dimetylpentylamin) |
• |
fenbutrazát |
• |
oxilofrin (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx x xxxx xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-dimetylpentylamin, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx a xxxx xxxxxxx, xxxx. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (adrenalin)4) |
• |
metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx] |
• |
xxxxxxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx;
• xxxxxxxx imidazolinu v xxxxxxx xxxxxx kožního, xxxxxxx, očního xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 20245).
X7 XXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx v této xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x, jsou xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx a xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (heroin) |
• |
metadon |
• |
oxykodon |
• |
tramadol |
|||
|
• |
oxymorfon |
S8 KANABINOIDY
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx zakázané xxxxx v xxxx xxxxx xxxx Specifické xxxxx. Návykové xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx přírodní x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.
• x xxxxxx (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx
• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)
• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx THC
VÝJIMKY
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.
Xxxxxxx glukokortikoidy xxxx zakázány, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx xxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Jiné xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx se xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X URČITÝCH SPORTECH
Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a xxx xx xx označeno xxxxxxxx (*) i Xxxx xxxxxx.
• xxxxxxxxxxx (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – skoky xx xxxxxx, akrobatické xxxxx / X-xxxxx x xxxxxxxxx X-xxxxx / xxx xxx
• xxxxxxxxxxxx xxxxx (XXX)
• podvodní xxxxxx (XXXX)* x xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx terč
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• xxxxx (XXX)
• xxxx (IGF)
• xxxxxxxx (XXX)
• střelba (ISSF, XXX)*
* xxxxxxxx xxxx Xxxx soutěž
Mimo xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;
1) xxxxx (x-xxxxxxxxxxxxxxxx) a jeho x-xxxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 ml.
2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx než 150 xxxxxxxxxx x 1 xx.
3) efedrin x metylefedrin: xxxxxxxx xxx koncentraci x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.
4) xxxxxxxxx (xxxxxxxxx): xxxx zakázáno xxxxxxx podávání, xxxx. xxxxx, xxxx, nebo xxxxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.
5) bupropion, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, pipradrol x xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024 x nejsou považovány xx Xxxxxxxx látky.
Xxxxxxxxx
Xxxxxx předpis x. 19/2025 Sb. nabyl xxxxxxxxx xxxx 28.1.2024.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx